Welcome to our dedicated page for Avalo Therapeutics news (Ticker: AVTX), a resource for investors and traders seeking the latest updates and insights on Avalo Therapeutics stock.
Avalo Therapeutics Inc (AVTX) is a clinical-stage biotechnology company pioneering therapies for immune dysregulation and inflammatory diseases. This dedicated news hub provides investors and industry professionals with timely updates on the company’s scientific advancements, regulatory milestones, and strategic developments.
Discover official press releases, clinical trial progress, and partnership announcements related to AVTX’s innovative pipeline – including its lead asset AVTX-009 and other biologics targeting critical immune pathways. Our curated collection ensures transparent access to essential updates without speculative commentary.
Key content categories include:
• Clinical trial results and regulatory submissions
• Research collaborations and licensing agreements
• Financial reporting and corporate communications
• Scientific presentations and peer-reviewed publications
Bookmark this page for streamlined tracking of Avalo’s progress in developing targeted therapies for complex inflammatory conditions. Check regularly for authoritative updates directly from company sources and verified industry reports.
Avalo Therapeutics (Nasdaq: AVTX) announced completion of enrollment in its Phase 2 LOTUS trial of AVTX-009 for adults with hidradenitis suppurativa (HS).
The trial exceeded its target of 222 patients with approximately 250 patients enrolled. LOTUS is a randomized, double-blind, placebo-controlled Phase 2 study (1:1:1) testing two AVTX-009 dose regimens versus placebo during a 16-week treatment phase. The primary endpoint is the proportion achieving HiSCR75 at Week 16. Secondary measures include HiSCR50/90, IHS4, draining fistula count, AN count, and PGA Skin Pain reductions. Topline data are expected in mid-2026. Trial identifiers: NCT06603077 and www.lotustrial.com.
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has announced two key leadership appointments. Taylor Boyd joins as Chief Business Officer, bringing 15 years of experience and a track record of executing over $40 billion in M&A and capital markets transactions. Ashley Ivanowicz joins as SVP of Human Resources with 20 years of biotech HR experience.
The appointments come as Avalo prepares for its LOTUS Phase 2 trial of AVTX-009 in hidradenitis suppurativa, with data expected mid-2026. As part of their inducement packages, Boyd and Ivanowicz received 275,000 and 100,000 stock options respectively, vesting over four years with a one-year cliff.
Avalo Therapeutics (Nasdaq: AVTX), a clinical stage biotech company focused on IL-1β-based treatments, has appointed Kevin R. Lind to its Board of Directors. Lind brings over 20 years of leadership experience in capital markets and business development, most notably leading Longboard Pharmaceuticals to a $2.6 billion acquisition by H. Lundbeck A/S in 2024.
The appointment comes as Avalo advances AVTX-009 through Phase 2 LOTUS trial in hidradenitis suppurativa (HS), with topline data expected mid-2026. Throughout his career, Lind has raised over a billion dollars for biotech companies and held key positions at Arena Pharmaceuticals, TPG, and Lehman Brothers.
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company focused on IL-1β-based treatments for immune-mediated inflammatory diseases, has announced its participation in three upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference (September 3), the H.C. Wainwright Global Investment Conference (September 9), and the Stifel Virtual Immunology and Inflammation Forum (September 15). All presentations will be available via webcast on the company's investor relations website, with replays accessible for at least 30 days.
Avalo Therapeutics (Nasdaq: AVTX), a clinical-stage biotech company focused on IL-1β-based treatments, reported Q2 2025 financial results and business updates. The company's Phase 2 LOTUS trial for hidradenitis suppurativa (HS) has enrolled over 75% of planned patients, with topline data expected mid-2026.
Financial highlights include $113.3 million in cash and short-term investments as of June 30, 2025, providing runway into 2028. Q2 2025 showed a net loss of $20.8 million ($1.92 per share), compared to net income of $98.5 million in Q2 2024. R&D expenses increased by $9.5 million to $14.1 million, primarily due to LOTUS trial costs.
The company strengthened its leadership by appointing Rita Jain, M.D. to the Board of Directors, bringing valuable experience in clinical development and regulatory strategy.
Avalo Therapeutics (NASDAQ: AVTX), a clinical stage biotech company specializing in immune dysregulation treatments, has announced its participation in two upcoming investor conferences in June 2025. The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, at 7:35 am ET in New York. Additionally, management will join a panel discussion titled "Dermatology: AA, HS, PSO" at the Oppenheimer Innovators in I&I Summit on June 25, 2025, at 10am ET in New York. Webcasts and replays will be available on the company's investor relations website for at least 30 days.
Avalo Therapeutics (NASDAQ: AVTX) reported its Q1 2025 financial results and business updates. The company ended Q1 with $125 million in cash, providing runway into 2027 with potential extension into 2028. The Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa (HS) is progressing as planned, with topline data expected in 2026.
Q1 2025 financial highlights include: net loss of $13.1 million ($1.25 per share), R&D expenses of $9.1 million (up $7.0M YoY), and G&A expenses of $5.5 million (up $2.4M YoY). The company is carefully evaluating the timing of additional development activities beyond LOTUS trial due to current market conditions.
Avalo Therapeutics, a clinical stage biotech company specializing in immune dysregulation treatments, has announced its upcoming participation in the Citizens Life Sciences Conference.
The company's CEO, Dr. Garry Neil, is scheduled to present at the conference on Thursday, May 8, 2025, at 3:00 pm ET in New York. The presentation will be accessible through live webcasts and replays from the company's website.
Investors and interested parties can access the presentation through:
- The "News / Events" section of Avalo's investor relations website at ir.avalotx.com
- Archived webcast replays available for a minimum of 30 days
FAQ
What is the current stock price of Avalo Therapeutics (AVTX)?
What is the market cap of Avalo Therapeutics (AVTX)?
